A Single Center Analysis of Thymic Neuroendocrine Tumors

Abstract

Purpose: Thymic neuroendocrine tumors (TNETs) are a collection of slow-progressing neoplasms located in the anterior mediastinum. Relatively few previously published studies have focused on thymic carcinomas. This study investigated the basic clinical characteristics, treatment, and prognosis of TNETs. Methods: Patients were enrolled in the study from January 2003 to December 2017 who had been diagnosed with TNETs through pathological screening and treated at our institution. Demographic data from each patient, the Masaoka stage, histology and size of the tumor, tumor invasion characteristics, and therapeutic strategies were gathered. The Kaplan–Meier method was used to assess patient survival. In addition, the log-rank test was used to carry out univariate analyses. Results: Twenty-six patients were eligible for inclusion in the study. The median age of the patients was 46.5 (25–69) years. The tumor median maximum diameter was 7.9 cm (from 3 to 19 cm). Twenty-four patients were treated surgically. Nineteen patients completed radiation therapy, and sixteen patients underwent chemotherapy. A median follow-up time of 54.95 months was observed. The survival rate for three years was 75.0% and 70.6% for five years. The corresponding progression-free survival rates for three and five years were 55.7% and 37.7%, respectively. The local, regional recurrence-free survival (LRFS) rates were 87.2% and 81.7%, and the distant metastasis-free survival (DMFS) rates were 55.7% and 37.7%, at three and five years, respectively. Local recurrence (six patients) and bone metastasis (six patients) were observed as the most frequent failures. Conclusion: TNET was observed to be an aggressive but rare malignant lesion. While the predominant treatment was complete resection, chemotherapy and radiotherapy were also required due to the high recurrence rate.

The combination of etoposide and platinum for the treatment of thymic neuroendocrine neoplasms: A retrospective analysis

“…The extreme rarity of TNENs has led to a lack of prospective clinical trials and large, high‐quality cohort studies. Only a few retrospective studies have investigated the prognosis of this disease 3,6,16 . Standard guidelines or expert consensus has not been established for the treatment of TNENs.…”

“…Only a few retrospective studies have investigated the prognosis of this disease. 3 , 6 , 16 Standard guidelines or expert consensus has not been established for the treatment of TNENs. For almost four decades, countless new drugs have been tested as standard treatments for SCLC; however, all have failed.…”